enGene Holdings Inc. Cash Flow Statement
ENGN / Health Care|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
enGene Holdings Inc. used $99M in operating cash flow and negative free cash flow of $101M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| Depreciation & Amortization | $500.0K | $300.0K | $200.0K | $200.0K |
| Operating Cash Flow | -$99.2M | -$48.3M | -$24.7M | -$17.6M |
| Capital Expenditures | $1.5M | $925.0K | $318.0K | $153.0K |
| Free Cash Flow | -$100.7M | -$49.2M | -$25.1M | -$17.7M |
| Dividends Paid | - | - | $0 | - |